JAZZ
NASDAQJazz Pharmaceuticals plc
Price$250.91+15.46 (+6.57%)
2026-05-282026-08-31
News · 26 weeks90-41%
2026-03-082026-08-30
Mix5390d
- Insider24(45%)
- SEC Filings15(28%)
- Other10(19%)
- Analyst2(4%)
- Earnings2(4%)
Latest news
25 items- INSIDEREVP, Global Head of R&D & CMO Iannone Robert sold $19,207,098 worth of Ordinary Shares (76,921 units at $249.70) as part of a pre-agreed trading plan and exercised 57,500 units of Ordinary Shares at a strike of $125.84, decreasing direct ownership by 23% to 65,686 units (SEC Form 4)4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)
- SECJazz Pharmaceuticals plc filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Other Events, Unregistered Sales of Equity Securities8-K - Jazz Pharmaceuticals plc (0001232524) (Filer)
- SECSEC Form 144 filed by Jazz Pharmaceuticals plc144 - Jazz Pharmaceuticals plc (0001232524) (Subject)
- SECSEC Form 144 filed by Jazz Pharmaceuticals plc144 - Jazz Pharmaceuticals plc (0001232524) (Subject)
- SECSEC Form 144 filed by Jazz Pharmaceuticals plc144 - Jazz Pharmaceuticals plc (0001232524) (Subject)
- PRZiihera® (zanidatamab-hrii) plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Versus Trastuzumab plus Chemotherapy in First-Line HER2+ Advanced GEAHERIZON-GEA-01 results reinforce recently FDA-approved Ziihera as the definitive HER2-targeted backbone therapy in first-line GEALonger follow up of Ziihera plus tislelizumab and chemotherapy shows improved OS hazard ratio, further supporting this regimen as the new standard of careData submitted for presentation in fourth quarter 2026For U.S. media and investors only DUBLIN, Aug. 31, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced second interim top-line overall survival (OS) results from the Phase 3 HERIZON-GEA-01 trial showing that Ziihera® (zanidatamab-hrii) in combination with chemotherapy demonstrated statistically significant and clinically meaningful impro
- PRJazz Pharmaceuticals Announces Pricing of Upsized Private Offering of $1.1 Billion of 1.875% Exchangeable Senior Notes due 2032 and Concurrent Ordinary Share RepurchasesDUBLIN, Aug. 27, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) ("Jazz Pharmaceuticals") announced the pricing of $1.1 billion aggregate principal amount of 1.875% exchangeable senior notes due 2032 (the "notes") in a private offering (the "offering") by Jazz Investments I Limited, its wholly-owned subsidiary (the "Issuer"), to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). The offering was upsized from the previously announced offering size of $1.0 billion aggregate principal amount of notes. The Issuer also granted the initial purchasers of the notes the right to purchase, exercisable within a 13-day pe
- PRJazz Pharmaceuticals Announces Private Offering of $1.0 Billion of Exchangeable Senior Notes due 2032 and Concurrent Ordinary Share RepurchasesDUBLIN, Aug. 26, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) ("Jazz Pharmaceuticals") today announced that Jazz Investments I Limited, its wholly-owned subsidiary (the "Issuer"), intends to offer, subject to market conditions and other factors, $1.0 billion aggregate principal amount of exchangeable senior notes due 2032 (the "notes") in a private offering (the "offering") to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). The Issuer also intends to grant the initial purchasers of the notes the right to purchase, exercisable within a 13-day period from, and including the initial issue date of the notes,
- SECJazz Pharmaceuticals plc filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Jazz Pharmaceuticals plc (0001232524) (Filer)
- PRU.S. FDA Approves Ziihera® (zanidatamab-hrii) with and without Tislelizumab plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal AdenocarcinomaZiihera plus tislelizumab and chemotherapy approved for first-line treatment of all HER2+ GEA patients (IHC 3+ and IHC 2+/ISH+) regardless of PD-L1 status, establishing a new standard of care in front-line GEACompany to host investor webcast on Aug. 25 at 4:30 p.m. ET For U.S. media and investors onlyDUBLIN, Aug. 25, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced that the U.S. Food and Drug Administration (FDA) approved two Ziihera® (zanidatamab-hrii)-containing regimens for the first-line treatment of adults with unresectable locally advanced or metastatic HER2-positive (HER2+) gastroesophageal adenocarcinoma (GEA): Ziihera plus Tevimbra® (tislelizumab-jsgr) and
- SECSEC Form 8-K filed by Jazz Pharmaceuticals plc8-K - Jazz Pharmaceuticals plc (0001232524) (Filer)
- SECJazz Pharmaceuticals plc filed SEC Form 8-K: Regulation FD Disclosure8-K - Jazz Pharmaceuticals plc (0001232524) (Filer)
- PRJazz Pharmaceuticals to Acquire Actio Biosciences, Expanding Rare Epilepsy PortfolioAdds ABS-1230, a clinical-stage, potential first-in-class precision therapy for KCNT1+ epilepsy Leverages Jazz development expertise and commercial strength in rare and severe epilepsiesTransaction includes $820 million upfront payment DUBLIN and SAN DIEGO, Aug. 10, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) and Actio Biosciences, Inc. (Actio Biosciences) today announced the companies have entered into a definitive agreement for Jazz to acquire privately-held Actio Biosciences for $820 million upfront and up to $500 million in contingent consideration.Actio Biosciences' lead clinical asset is ABS-1230, a novel, first-in-class small molecule precision therapy KCNT1 ion channe
- INSIDEREVP, Chief Commercial Officer Pearce Samantha covered exercise/tax liability with 780 units of Ordinary Shares, decreasing direct ownership by 2% to 47,131 units (SEC Form 4) to satisfy withholding tax4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)
- INSIDERDirector Winningham Rick E was granted 1,605 units of Ordinary Shares, increasing direct ownership by 17% to 11,172 units (SEC Form 4)4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)
- INSIDERDirector Love Ted W was granted 1,605 units of Ordinary Shares, increasing direct ownership by 105% to 3,132 units (SEC Form 4)4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)
- INSIDERDirector Hamill Laura was granted 1,605 units of Ordinary Shares, increasing direct ownership by 23% to 8,538 units (SEC Form 4)4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)
- INSIDERDirector Kennedy Patrick was granted 1,605 units of Ordinary Shares, increasing direct ownership by 24% to 8,307 units (SEC Form 4)4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)
- INSIDERDirector Smith Mark Douglas was granted 1,605 units of Ordinary Shares, increasing direct ownership by 17% to 11,285 units (SEC Form 4)4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)
- INSIDERDirector Cook Jennifer E. was granted 1,605 units of Ordinary Shares, increasing direct ownership by 15% to 12,442 units (SEC Form 4)4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)
- INSIDERDirector Mulligan Seamus was granted 1,605 units of Ordinary Shares, increasing direct ownership by 0.14% to 1,184,633 units (SEC Form 4)4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)
- INSIDERDirector Mcsharry Heather Ann was granted 1,605 units of Ordinary Shares, increasing direct ownership by 9% to 20,054 units (SEC Form 4)4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)
- INSIDERDirector Enright Patrick G was granted 1,605 units of Ordinary Shares, increasing direct ownership by 8% to 22,984 units (SEC Form 4)4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)
- INSIDERDirector Riedel Norbert G was granted 1,605 units of Ordinary Shares, increasing direct ownership by 23% to 8,629 units (SEC Form 4)4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)
- INSIDERDirector Cozadd Bruce C was granted 1,605 units of Ordinary Shares, increasing direct ownership by 0.44% to 362,287 units (SEC Form 4)4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)
JAZZ FAQ
7 questionsWhat does Jazz Pharmaceuticals plc do?
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older...Where does JAZZ stock trade?
Jazz Pharmaceuticals plc (JAZZ) is listed on NASDAQ.What sector and industry is JAZZ in?
Jazz Pharmaceuticals plc operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Jazz Pharmaceuticals plc go public?
Jazz Pharmaceuticals plc (JAZZ) completed its IPO in 2007.What are analysts saying about JAZZ?
Jazz Pharmaceuticals plc has had 8 recent analyst actions on file. The most recent action was from Canaccord Genuity: Buy on 2026-07-17.What companies are similar to JAZZ?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare JAZZ side-by-side with any of them on Quantisnow.How can I track JAZZ on Quantisnow?
Quantisnow aggregates Jazz Pharmaceuticals plc's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow JAZZ to receive live email and push alerts on every new disclosure.